Our special guest tonight is Daniel Brennan who joined Lundbeck in July 2009, after Xenazine had been developed and launched in the USA. He is Vice President and General Manager of Neurology Franchise at Lundbeck and now leads the group of people that distribute, provide information, and support Xenazine as well as other nervous system therapies for rare diseases. He enjoys meeting people in the HD community to better understand the impact that this disease has on people and their families, as well as learn what they can do better as a company as they continue to make the medicine available to the public. Lundbeck has become very involved and dedicated to Huntington's Disease and recently announced their commitment to research for HD that may halt or slow the progression of the disease. He’d like to make sure that he understands your concerns and also try to provide information that may be helpful in your understanding of Lunbeck’s actions and activities.

Ver todos los episodios